Ovarian cancer has poor survival rates due to a combination of diagnosis at advanced
disease stages and disease recurrence as a result of platinum chemotherapy resistance …

There is no consensus on the syntheses concerning the impact of BRCA mutation on
ovarian cancer survival. A systematic review and meta-analysis of observational studies was …

Ovarian cancer is among the most lethal gynecologic malignancies with a poor survival
prognosis. The current therapeutic strategies involve surgery and chemotherapy. Research …

Objective: A meta-analysis was performed to determine if BRCA1/2 mutations are
associated with improved overall survival (OS) and progression-free survival (PFS) in …

Introduction One of the most significant risk factors for the development of ovarian cancer
(OC) is a genetic mutation in BRCA1 (breast cancer gene 1) or BRCA2. Here we describe …

Ovarian cancer (OC) is an important cause of gynecologic cancer-related deaths. In Mexico,
around 4700 new cases of OC are diagnosed per year and it represents the second cause …

Ovarian cancer (OC) is the second most common cause of death in women with
gynecological cancer. Considering the poor prognosis, particularly in the case of platinum …

Objectives We evaluated in a large study meta-database of prospectively randomised phase
III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in …

Ovarian cancer survival rates have improved only slightly in recent decades; however,
treatment of this disease is expected to undergo rapid change as strategies incorporating …

Aim of work Reporting the incidence and the variants of BRCA1/2 mutations in ovarian
cancer patients exploring their effects on the treatment outcomes. Patients and methods In …